Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARQT

ARQT - Arcutis Biotherapeutics Inc Stock Price, Fair Value and News

$25.45-0.88 (-3.34%)
Market Closed

53/100

ARQT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

ARQT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$26.93

Target 3M

$26.38

Target 6M

$26.57

ARQT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARQT Price Action

Last 7 days

-4.7%

Last 30 days

-10.9%

Last 90 days

2.1%

Trailing 12 Months

82.7%

ARQT RSI Chart

ARQT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARQT Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-70.33

Price/Sales (Trailing)

9.81

Price/Free Cashflow

-93.77

ARQT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$26.93

Target 3M

$26.38

Target 6M

$26.57

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

317.9M

Rev. Growth (Yr)

121.69%

Rev. Growth (Qtr)

21.74%

ARQT Earnings

Earnings (TTM)

-44.3M

Earnings Growth (Yr)

117.84%

Earnings Growth (Qtr)

146.64%

ARQT Profitability

Operating Margin

98.99%

Return on Equity

-28.04%

Return on Assets

-11.95%

Free Cashflow Yield

-1.07%

ARQT Investor Care

Shares Dilution (1Y)

4.65%

Diluted EPS (TTM)

-0.35

ARQT Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025212.8M263.5M317.9M0
2024106.4M132.1M138.7M196.5M
202317.7M31.6M45.6M59.6M
20220003.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arcutis Biotherapeutics Inc

ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
 CEO
 WEBSITEarcutis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES268

Arcutis Biotherapeutics Inc Frequently Asked Questions

ARQT is the stock ticker symbol of Arcutis Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arcutis Biotherapeutics Inc is 3.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARQT's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARQT is over valued or under valued. Whether Arcutis Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Arcutis Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARQT.

As of Wed Jan 28 2026, ARQT's PE ratio (Price to Earnings) is -70.33 and Price to Sales (PS) ratio is 9.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARQT PE ratio will change depending on the future growth rate expectations of investors.